Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells

Christopher C. Kloss(Memorial Sloan Kettering Cancer Center), Maud Condomines(Memorial Sloan Kettering Cancer Center), Marc Cartellieri(TU Dresden), Michael Bachmann(University Hospital Carl Gustav Carus), Michel Sadelain(Memorial Sloan Kettering Cancer Center)

Nature Biotechnology

December 16, 2012

10.1038/nbt.2459

Cited by 858Open Access

Abstract

Related Papers

Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2

Richard A. Morgan, James C. Yang, Mio Kitano et al.|Molecular Therapy|2010|2.5k

B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor–transduced T cells

James N. Kochenderfer, Mark E. Dudley, Steven A. Feldman et al.|Blood|2011|1.4k

Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias

Renier J. Brentjens, Isabelle Rivière, Jae H. Park et al.|Blood|2011|1.3k

IL-2 family cytokines: new insights into the complex roles of IL-2 as a broad regulator of T helper cell differentiation

Wei Liao, Jian‐Xin Lin, Warren J. Leonard|Current Opinion in Immunology|2011|736

Cloning immunoglobulin variable domains for expression by the polymerase chain reaction.

Rosaria Orlandi, Detlef Güssow, Patricia Jones et al.|Proceedings of the National Academy of Sciences|1989|707